OA12878A - Method of promoting smoking cessation. - Google Patents
Method of promoting smoking cessation. Download PDFInfo
- Publication number
- OA12878A OA12878A OA1200400348A OA1200400348A OA12878A OA 12878 A OA12878 A OA 12878A OA 1200400348 A OA1200400348 A OA 1200400348A OA 1200400348 A OA1200400348 A OA 1200400348A OA 12878 A OA12878 A OA 12878A
- Authority
- OA
- OAPI
- Prior art keywords
- smoking
- composition
- reboxetine
- nicotine
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39289302P | 2002-07-01 | 2002-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12878A true OA12878A (en) | 2006-09-15 |
Family
ID=30000949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200400348A OA12878A (en) | 2002-07-01 | 2003-06-26 | Method of promoting smoking cessation. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040102440A1 (sr) |
| EP (1) | EP1534254A2 (sr) |
| JP (1) | JP2005531631A (sr) |
| CN (1) | CN1665511A (sr) |
| AP (1) | AP2004003188A0 (sr) |
| AU (1) | AU2003253609A1 (sr) |
| BR (1) | BR0312293A (sr) |
| CA (1) | CA2491549A1 (sr) |
| EA (1) | EA200401584A1 (sr) |
| EC (1) | ECSP045517A (sr) |
| HR (1) | HRP20041194A2 (sr) |
| IL (1) | IL165882A0 (sr) |
| IS (1) | IS7600A (sr) |
| MA (1) | MA27597A1 (sr) |
| MX (1) | MXPA05000296A (sr) |
| NO (1) | NO20045535L (sr) |
| OA (1) | OA12878A (sr) |
| PL (1) | PL373620A1 (sr) |
| RS (1) | RS115204A (sr) |
| TN (1) | TNSN04267A1 (sr) |
| WO (1) | WO2004002463A2 (sr) |
| ZA (1) | ZA200410339B (sr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| WO2004056363A2 (en) | 2002-12-20 | 2004-07-08 | Niconovum Ab | A physically and chemically stable nicotine-containing particulate material |
| DK2316456T3 (en) | 2003-04-29 | 2017-09-11 | Orexigen Therapeutics Inc | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
| EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| EP2474308A1 (en) * | 2005-06-27 | 2012-07-11 | Valeant International (Barbados) SRL | Pharmaceutical formulations containing bupropion hydrobromide |
| ES2402522T3 (es) | 2005-11-22 | 2013-05-06 | Orexigen Therapeutics, Inc. | Composiciones y procedimientos para aumentar la sensibilidad a la insulina |
| CA2646942C (en) | 2006-03-16 | 2014-07-29 | Niconovum Ab | Improved snuff composition |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| US20070297991A1 (en) * | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Neural conduit agent dissemination for smoking cessation and other applications |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| WO2009004621A1 (en) * | 2007-07-02 | 2009-01-08 | Technion Research & Development Foundation Ltd. | Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage |
| JP2011521973A (ja) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| US20110046116A1 (en) | 2009-08-20 | 2011-02-24 | Cukrowski Walter J | Sedative for use during eye surgery |
| WO2011041451A2 (en) * | 2009-09-30 | 2011-04-07 | Harlan Clayton Bieley | Smoking cessation with body weight maintenance and nutritional supplement |
| CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
| AU2011274423B2 (en) | 2010-07-09 | 2016-02-11 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
| LT3730132T (lt) | 2012-06-06 | 2022-08-25 | Nalpropion Pharmaceuticals Llc | Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde |
| US20160256472A1 (en) * | 2013-10-14 | 2016-09-08 | Palmaya Pty Ltd | Compositions and methods of administering same |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| CN104381577A (zh) * | 2014-11-18 | 2015-03-04 | 安徽润康保健食品有限公司 | 一种具有戒烟功能的口香糖 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2244189T3 (es) * | 1998-04-09 | 2005-12-01 | PHARMACIA & UPJOHN COMPANY LLC | Uso de reboxetina para el tratamiento de trastornos neuropsiquiatricos. |
| CN1300217A (zh) * | 1998-05-08 | 2001-06-20 | 法玛西雅厄普约翰美国公司 | 瑞波西汀与吲哚洛尔的新的药物组合 |
| SK286104B6 (sk) * | 1999-07-01 | 2008-03-05 | Pharmacia & Upjohn Company | Použitie (S,S) reboxetínu na prípravu lieku na liečenie alebo prevenciu chronickej bolesti |
| DE10004547A1 (de) * | 2000-02-02 | 2001-08-09 | Liedtke Pharmed Gmbh | Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe |
-
2003
- 2003-06-24 US US10/602,447 patent/US20040102440A1/en not_active Abandoned
- 2003-06-26 EA EA200401584A patent/EA200401584A1/ru unknown
- 2003-06-26 OA OA1200400348A patent/OA12878A/en unknown
- 2003-06-26 PL PL03373620A patent/PL373620A1/xx not_active Application Discontinuation
- 2003-06-26 MX MXPA05000296A patent/MXPA05000296A/es not_active Application Discontinuation
- 2003-06-26 RS YUP-1152/04A patent/RS115204A/sr unknown
- 2003-06-26 WO PCT/US2003/016232 patent/WO2004002463A2/en active Application Filing
- 2003-06-26 AP AP200403187D patent/AP2004003188A0/xx unknown
- 2003-06-26 AU AU2003253609A patent/AU2003253609A1/en not_active Abandoned
- 2003-06-26 CA CA002491549A patent/CA2491549A1/en not_active Abandoned
- 2003-06-26 JP JP2004517572A patent/JP2005531631A/ja active Pending
- 2003-06-26 CN CN038156369A patent/CN1665511A/zh active Pending
- 2003-06-26 EP EP03761901A patent/EP1534254A2/en not_active Ceased
- 2003-06-26 BR BR0312293-0A patent/BR0312293A/pt not_active IP Right Cessation
-
2004
- 2004-12-16 IS IS7600A patent/IS7600A/is unknown
- 2004-12-16 HR HR20041194A patent/HRP20041194A2/xx not_active Application Discontinuation
- 2004-12-17 MA MA28018A patent/MA27597A1/fr unknown
- 2004-12-17 NO NO20045535A patent/NO20045535L/no not_active Application Discontinuation
- 2004-12-20 IL IL16588204A patent/IL165882A0/xx unknown
- 2004-12-22 ZA ZA200410339A patent/ZA200410339B/en unknown
- 2004-12-28 EC EC2004005517A patent/ECSP045517A/es unknown
- 2004-12-30 TN TNP2004000267A patent/TNSN04267A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS115204A (en) | 2007-02-05 |
| WO2004002463A3 (en) | 2004-02-19 |
| ECSP045517A (es) | 2005-03-10 |
| AU2003253609A1 (en) | 2004-01-19 |
| PL373620A1 (en) | 2005-09-05 |
| JP2005531631A (ja) | 2005-10-20 |
| CA2491549A1 (en) | 2004-01-08 |
| EA200401584A1 (ru) | 2005-08-25 |
| MXPA05000296A (es) | 2005-08-19 |
| HRP20041194A2 (en) | 2005-06-30 |
| US20040102440A1 (en) | 2004-05-27 |
| CN1665511A (zh) | 2005-09-07 |
| TNSN04267A1 (fr) | 2007-03-12 |
| AP2004003188A0 (en) | 2004-12-31 |
| BR0312293A (pt) | 2005-04-12 |
| ZA200410339B (en) | 2006-07-26 |
| MA27597A1 (fr) | 2005-11-01 |
| EP1534254A2 (en) | 2005-06-01 |
| WO2004002463A2 (en) | 2004-01-08 |
| IS7600A (is) | 2004-12-16 |
| NO20045535L (no) | 2005-01-27 |
| IL165882A0 (en) | 2006-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA12878A (en) | Method of promoting smoking cessation. | |
| CA2305799C (en) | Composition for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug | |
| US20020019421A1 (en) | Compositions and therapy for substance addiction | |
| JP2009517393A (ja) | 不安症の治療方法 | |
| EA003142B1 (ru) | Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения | |
| KR20070032619A (ko) | 폐동맥 고혈압의 치료를 위한 일로프로스트의 복합 치료제 | |
| JP2005500298A (ja) | 嗜癖物質または麻薬に対する依存症を医薬を用いて処置するための活性成分の組み合わせ | |
| PL204075B1 (pl) | Zastosowanie kompozycji farmaceutycznej zawierającej metoklopramid oraz tramadol do wytwarzania leku | |
| CA2429047A1 (en) | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine | |
| CZ301210B6 (cs) | Použití desoxypeganinu k ošetrování klinické deprese | |
| Glynn et al. | Update on smoking cessation therapies | |
| KR20050016679A (ko) | 금연을 촉진시키는 방법 | |
| AU2002354856B2 (en) | Active substance combination for medicamentous therapy of nicotine dependency | |
| CA2338326A1 (en) | Use of moclobemide and metabolites for treating and preventing substance abuse | |
| ZA200507213B (en) | Combination of desoxypeganine and mecamylamine forthe treatment of alcohol abuse | |
| TW574037B (en) | Nicotine addiction treatment | |
| AU5335000A (en) | New treatment using phenethylamine derivatives | |
| MXPA06003273A (en) | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |